October 1, 2025Journal of Clinical Oncology

Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results

View Full Paper

Ask AI

Bookmark

Authors

MWMatthew J. WieduwiltAtrium Health Wake Forest Baptist JYJun Yin OKOudom Kour

Discussion

Member takes

Implication

This cohort study demonstrates a high remission rate with chemotherapy-free treatment in older adults, suggesting a new standard for b-cell ALL management.

Key Points

The regimen resulted in a composite complete remission rate of 97% targeting b-cell ALL in older patients.
At a median follow-up of 30 months, the 1-year event-free survival was 75%, indicating a significant improvement in outcomes.
Eligible patients received inotuzumab ozogamicin followed by blinatumomab, showing promise in avoiding conventional chemotherapy.
This treatment approach may enable better outcomes in older adults with limited options due to previous treatment toxicity.

Cite This Study

Wieduwilt et al. (2025) studied this question.

synapsesocial.com/papers/68dd91cbfe798ba2fc4989ff https://doi.org/10.1200/jco-25-00307

View Full Paper

Ask AI

Bookmark

Implication

This cohort study demonstrates a high remission rate with chemotherapy-free treatment in older adults, suggesting a new standard for b-cell ALL management.

Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results

Discussion

Member takes

Implication

Key Points

Cite This Study

Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider